Membrane-Spanning 4-Domains, Subfamily A, Member 1 Proteins (MS4A1)

Human Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1) interaction partners

1. Older age and CD20 expression are significant and favorable independent prognostic factors of HHV-8-negative effusion-based lymphoma.

2. Case Report: indolent T-cell lymphoproliferative disorder with aberrant CD20 expression involving the gastrointestinal tract and bone marrow.

3. Our study found that a small subset of papillary thyroid carcinomas (<10%, mainly of classic variant) exhibited aberrant membranous expression of CD20

4. Our results support the fact that CD200 can be added to routine Chronic lymphoproliferative disorders panel as it is useful in subcategorizing them. However, inclusion of CD20 ABC to routine panel does not seem plausible but may be done for difficult diagnostic cases or where anti-CD20 therapy is planned.

5. showed here that 3' UTR NOTCH1 mutations are associated with low CD20 expression and with relative resistance to anti-CD20 immunotherapy in vitro

6. We conclude that the relationship between complement-regulatory proteins CFHR1 and CFHR3 and response to anti-CD20 mAb therapy varies based on the specific anti-CD20 mAb used.

7. the immunohistochemical staining patterns of CD3 and CD20 in Malignant Lymphoma Cells, were investigated.

8. Limiting the antibody-induced induction of immunosuppressive reactive oxygen species may improve the anti-leukemic efficacy of anti-CD20 therapy in chronic lymphocytic leukemia.

9. Case Report: primary cutaneous T-cell lymphoma with aberrant CD20 expression.

10. Data suggest that insulitis (destruction of pancreatic beta-cells and their ability to produce/secrete insulin) occurs in two distinct profiles in type 1 diabetes; these differ in proportion of CD20-positive B-lymphocytes (relative to CD4-positive T-lymphocytes) present within the infiltrate; greater infiltration of CD20-positive B-lymphocytes leads to more aggressive disease progression.

11. PZ-DHA also arrested MDA-MB-231 cell division at the G2/M phase and down-regulated expression of cyclin B1 and cyclin-dependent kinase 1 (CDK1)

12. there is a high CD23a/CD23b ratio of chronic lymphocytic leukemia cells, which demonstrates that in a subset of CLL cases, low CD23 expression together with high CD20 and CD38 expressions may serve as a surrogate for trisomy 12

13. IL-17-producing pathogenic T lymphocytes co-express CD20 in primary Sjogren's syndrome patients.

14. Studies indicate that CD20 antigen expression is absent in a variety of diffuse large B cell lymphomas (DLBCLs), including plasmablastic lymphoma, primary effusion lymphoma, anaplastic lymphoma, kinase-positive DLBCL, and large B cell lymphoma arising in human herpesvirus 8-associated multicentric Castleman disease.

15. lipid formulations based on a polyplex or lipoplex backbone additionally equipped with anti-CD20 antibodies are promising non-viral vectors for specific oligonucleotide transfer into human tumor cells.

16. The ABC values obtained for CD20 expression levels using PE, APC, or PerCP Cy5.5 are consistent over the five different instrument platforms for any given apparently healthy donor independent of the fluorochrome used

17. Data indicate that Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) patients who presented with cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) deletion showed a higher rate of CD20 antigen expression.

18. the findings demonstrate that treatment with anti-CD20-hIFNalpha reverses resistance of B-NHL

19. Case Report: aberrant CD20 expression by skin-infiltrating T cells using multispectral imaging.

20. Microenvironment CD20 + cells seem to play a favorable prognostic role in classical Hodgkin Lymphoma. Depletion of CD20 + cells together with an increase of TAMs identifies a group of patients with high-risk disease.

Mouse (Murine) Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1) interaction partners

1. Our findings indicate that anti-CD20-IFNalpha eradicates B-cell lymphoma by employing tumor cells as antigen-presenting cells to reactivate tumor-infiltrating CD8(+) T cells and synergizing with anti-PD-L1 treatment

2. Galectin-1 has a role in driving lymphoma CD20 immunotherapy resistance in a mouse model

3. Results indicate that an antigen-specific B cell response towards intracellular pathogens can be generated during anti-CD20 depletion therapy.

4. this study demonstrates a role for CD20 in B cell activation and T-dependent humoral immunity.

5. CD20 is required for store-operated calcium entry in C2C12 myoblasts.

6. immunization of mice with the CD20 extracellular domain-6 using Freund's or QS-21 adjuvants was shown to exert significant biological effects in vivo with the pronounced depletion of splenic B cells.

7. type I CD20 antibody cytotoxicity critically depends on Fc receptor ITAM signaling

8. CD20 deficiency in humans results in impaired T cell-independent antibody responses.

9. review of structure, function, tissue and cell distribution

10. Anti-CD20 antibodies rapidly depleted the vast majority of circulating and tissue B cells in an isotype-restricted manner dependent on effector cell Fc receptor expression.

11. expression in bacterial cells; isolation and biophysical and structural studies

12. In mice treated with anti-CD20 mAb, development of arthritis was significantly reduced in comparison to control mAb-treated mice

13. involvement of CD20 in calcium influx

Rhesus Monkey Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1) interaction partners

1. Data show that the CD1c+ cells were found to be mononuclear leukocytes rather than granulocytes, and most of them expressed CD20.